Lantern Pharma (Nasdaq: LTRN) has reported a complete metabolic response in a Phase 1 trial patient with aggressive, treatment-resistant DLBCL after just two cycles of its AI-designed drug LP-284 — a first for the compound. Backed by Lantern’s RADR® platform, the result highlights LP-284’s potential to address a $4B global B-cell cancer market and redefine treatment options for patients with limited alternatives.

Minovia Therapeutics, which recently signed a definitive business combination agreement with Launch One Acquisition Corp. (Nasdaq: LPAA), has announced interim Phase 2 data for MNV-201, its mitochondrial cell therapy, showing no treatment-related serious adverse events and early signs of efficacy in Pearson Syndrome, a fatal pediatric mitochondrial disorder. Backed by FDA Fast Track and Rare Pediatric Disease designations, MNV-201’s novel approach is gaining momentum, with growth improvements seen in two of the first three patients and registrational trials targeted for 2026.

Trinity Biotech (Nasdaq: TRIB) has unveiled CGM+, a next-gen AI-native biosensor platform set to transform diabetes and wellness monitoring by fusing glucose tracking with real-time heart, temperature, and activity data in one sleek wearable. Positioned at the intersection of the $260B wearable AI, $200B AI healthcare, and $28B CGM markets, CGM+ opens up diverse revenue streams—from device sales to AI-driven insights—ahead of a planned commercial launch in mid-2026.

BullFrog AI (Nasdaq: BFRG) has released a new white paper detailing how its proprietary bfLEAP™ platform is redefining drug R&D by tackling biological complexity with causal, composition-aware AI. Positioned to disrupt the $35B AI-driven drug discovery market, bfLEAP™ offers actionable insights from target discovery to trial optimization—boosting confidence in therapeutic success where nearly 90% of candidates typically fail.